During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

The FDA has already made more than a dozen cancer drug approval decisions this year and more expected in the next several ...

A ChatGPT-like model can diagnose cancer, assist in selecting treatment options, and predict survival outcomes across various ...

JACKSON, Miss. (WJTV) – Registration is open for the University of Mississippi Medical Center (UMMC) Cancer Center and ...

SAN ANTONIO, October 16, 2024--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique ...

Cervical cancer remains the most widespread cause of cancer death in women in the country, accounting for 12 percent of all cancer deaths recorded in Zimbabwe. Prostate cancer is the second most ...

The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...

Cancer rates have been on the rise. Processed foods, a sedentary lifestyle, rising rates of obesity and alcohol use all ...

Asian Breast Center CEO, Dr. Norman San Agustin, told GMA News Online that the survival rate of breast cancer in the ...

Patients, pathologists, clinicians, researchers, radiologists and others from around the world recently gathered for the 2024 ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

The company continues to build validation data and believes its lower cost proposition can help it gain leverage in the European market where molecular tests are not reimbursed.